Plecanatide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 3 mg
Reference Brands: Trulance (USA)
Category:
Gastrointestinal Drugs
Plecanatide is available in Tablets
and strengths such as 3 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Plecanatide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Plecanatide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Plecanatide is a guanylate cyclase-C agonist approved by the US Food and Drug Administration for the treatment of adults with chronic idiopathic constipation (CIC). Chronic constipation significantly affects quality of life and healthcare utilization, and plecanatide represents a newer therapeutic option within the intestinal secretagogue class. It is a 16-amino-acid synthetic peptide and a structural analog of the human hormone uroguanylin, designed to act locally within the intestinal lumen.
Plecanatide works by activating guanylate cyclase-C receptors on the intestinal epithelium, increasing cyclic GMP levels, which promotes fluid secretion and accelerates intestinal transit. Clinical efficacy and safety were demonstrated in two large randomized, double-blind, placebo-controlled trials in adults with CIC. Treatment with plecanatide at doses of 3 mg and 6 mg resulted in a significantly higher proportion of durable complete spontaneous bowel movement responders compared with placebo. In addition, plecanatide significantly improved associated symptoms such as straining, stool consistency, and bloating.
Patients treated with plecanatide reported high satisfaction levels, improved quality of life, and willingness to continue therapy. The medication was generally well tolerated, with a low incidence of treatment-emergent adverse events, including diarrhea. Plecanatide’s targeted luminal action and favorable safety profile make it an effective option for long-term management of chronic idiopathic constipation.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing